Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Open-Label, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of Asp-001, 2 Mg And 5 Mg Orally Disintegrating Tablets (Formulations A And B) With Sibelium® 5 Mg Tablet in Healthy Participants

NCT07445464 is registered in ClinicalTrials.gov with Aspartes Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07445464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07445464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Open-Label, Single-Dose, Five-Way Crossover Study to Compare the Pharmacokinetics of Asp-001, 2 Mg And 5 Mg Orally Disintegrating Tablets (Formulations A And B) With Sibelium® 5 Mg Tablet in Healthy Participants
Lead sponsor
Aspartes Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2026
Completion date
August 27, 2026
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetic analysis